Fernanda Mosele
Institut Gustave Roussy · 26 works · 2,535 citations · h-index 13
Top works
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
- Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
- Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
- Genomics to select treatment for patients with metastatic breast cancer
- Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study
- Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)
- Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?
- ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.
- Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer
- Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients
- Optimizing the potential of antibody–drug conjugates in oncology
- Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer
- The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers
- Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine
- Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation
- Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2 -Driven Tumors
- Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers
- Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?
- Abstract P2-08-27: ICARUS-BREAST02: Safety, Tolerability, & Anti-tumor Activity of patritumab deruxtecan (HER3-DXd) monotherapy & combinations in patients (pts) with inoperable advanced breast cancer (ABC) following progression on trastuzumab deruxtecan (T-DXd)